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Heme oxygenase (HO)-1 is an inducible enzyme that cata-
lyzes the first and rate-limiting step in the oxidative degrada-
tion of free heme into ferrous iron, carbon monoxide (CO), 
and biliverdin (BV), the latter being subsequently converted 
into bilirubin (BR). HO-1, once expressed during inflam-
mation, forms high concentrations of its enzymatic by-prod-
ucts that can influence various biological events, and this ex-
pression is proven to be associated with the resolution of 
inflammation. The degradation of heme by HO-1 itself, the 
signaling actions of CO, the antioxidant properties of 
BV/BR, and the sequestration of ferrous iron by ferritin all 
concertedly contribute to the anti-inflammatory effects of 
HO-1. This review focuses on the anti-inflammatory mecha-
nisms of HO-1 actions and its roles in inflammatory diseases. 
[Immune Network 2009;9(1):12-19]
INTRODUCTION
Heme is inherently dangerous when, in excessive amounts, 
released from intracellular heme-containing proteins (1). The 
released  heme,  or  free  heme,  may  cause  oxidative  and  in-
flammatory  injury  associated  with  the  pathology  of  diverse 
conditions (2). Thus, it is of most importance to remove ex-
cess of free heme at sites of injury. The microsomal enzyme 
heme oxygenase (HO) catalyzes the first and rate-limiting step 
in the oxidative degradation of free heme to produce carbon 
monoxide (CO), ferrous iron (Fe
2+), and biliverdin (BV) (3). 
BV formed in this reaction is subsequently converted into bi-
lirubin (BR) by a BV reductase, and the ferrous iron is rapidly 
sequestered by ferritin and recycled for heme synthesis (4). 
To date, two genetically distinct isozymes of HO have been 
characterized: an inducible form, heme oxygenase-1 (HO-1), 
and a constitutively expressed form, heme oxygenase-2 (HO-2) 
(5). Although both HO-1 and HO-2 catalyze the identical bio-
chemical  reaction,  there  are  some  fundamental  differences 
between the two in genetic origin, primary structure, and mo-
lecular  weight  (4).  HO-1,  once  expressed  under  various 
pathological  conditions,  has  an  ability  to  metabolize  high 
amounts of free heme to produce high concentrations of its 
enzymatic by-products that, as such a consequence, can influ-
ence various biological events, and has recently been the fo-
cus  of  considerable  medical  interest  (6).  HO-1  can  be  ex-
pressed not only by its substrate, free heme, but also by a 
w i d e  v a r i e t y  o f  p r o - i n f l a m m a t o r y  s t i m u l i ,  s u g g e s t i n g  t h a t  
HO-1,  besides  its  fundamental  role  in  heme  degradation, 
plays other important roles in resolution of inflammation (7). 
In  this  regard,  this  review  has  focused  on  the  anti-in-
flammatory mechanisms of HO-1 actions and its roles in in-
flammatory diseases. This information is important for the de-
velopment of potential drugs that may alleviate the numerous 
inflammatory diseases through activation of HO-1 expression.
REGULATION OF HO-1 EXPRESSION
There  may  be  the  potential  interplay  between  intracellular 
and nuclear signaling events that lead to transcriptional acti-
vation  of  the  ho-1 g e n e  b y  v a r i o u s  s t i m u l i .  V a r i o u s  t r a n -
scription factors, including the nuclear factor E2-related factor 
2  (Nrf2),  interact  with  their  cognate  DNA  binding  domains 
in the HO-1 promoter to up-regulate ho-1 gene transcription, 
and a number of intracellular signaling molecules, including 
the mitogen-activated protein kinase (MAPK), involve the acti-Heme Oxygenase-1: Its Therapeutic Roles in Inflammatory Diseases
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Figure 1. Induction of HO-1 and subsequent production of heme 
degradation products exert potent anti-oxidative, anti-inflammatory 
and anti-apoptotic functions for the tissue homeostasis. HO-1 can be 
expressed by a number of stimuli mainly via MAPK-dependent Nrf2 
activation. These inducers of HO-1 include free heme, inflammatory 
mediators, oxidative stress, IL-10, and some inflammatory drugs. 
HO-1, once expressed under pathological conditions, can degrade free
heme into BV, CO, and Fe
2+. BV is converted into BR by BV reduc-
tase. The iron is rapidly sequestered by ferritin. Heme degradation 
products have been shown to modulate inflammatory response, 
perhaps by reducing oxidative stress, blocking MAPK pathways, and 
suppressing NF-κB activity.
vation of these transcription factors (8,9). The MAPK family 
comprises three primary signaling cascades: the extracellular 
signal regulated kinase (ERK), the c-Jun NH2-terminal kinase 
(JNK), and the p38 MAPK. Depending on the specific stim-
ulus and the cell type involved, one or more of MAPK path-
ways may involve HO-1 expression (10). The involvement of 
Nrf2 in HO-1 expression has been highlighted by the finding 
that  HO-1  is  less  inducible  in  Nrf2-deficient  mice  (11).  It 
should be noted that Nrf2 activation in response to the specif-
ic stimulus generally requires MAPK activation. For examples, 
Kim and co-workers (12) demonstrated that 15-Deoxy-∆
12,14- 
prostaglandin J2 induced HO-1 expression through activation 
o f  E R K  a n d  o t h e r  k i n a s e  p a t h w a y s  t h a t  l e a d s  t o  N r f 2  
activation. The antioxidant quercetin protected human hep-
atocytes from ethanol-induced oxidative stress via Nrf2- de-
pendent HO-1 expression, and p38 MAPK and ERK mediated 
quercetin-induced  Nrf2  activation  (13). 
REACTION PRODUCTS OF HO-1 AND THEIR 
ANTI-INFLAMMATORY ROLES
HO-1 expression is up-regulated in response to various forms 
of inflammatory stimuli, and this is associated with reduced 
inflammation  (14).  However,  the  mechanism(s)  of  anti-in-
flammatory  actions  of  HO-1  has  not  been  completely 
elucidated. It is most likely that the anti-inflammatory effects 
afforded by HO-1 may be attributed not only to its own action 
but also to other actions of three by-products of HO-1 activity 
(6). On other words, the degradation of the pro-oxidant heme 
by HO-1 itself, the signaling actions of CO, the antioxidant 
properties  of  BV/BR,  and  the  sequestration  of  free  iron  by 
ferritin  could  all  concertedly  contribute  to  the  anti-in-
flammatory effects observed with HO-1 (Fig. 1). The follow-
ings briefly describe the mechanisms that may explain the an-
ti-inflammatory  actions  of  HO-1.
CO
The gaseous molecule CO seems to be responsible for most 
of  the  anti-inflammatory  actions  of  HO-1  (15).  In  macro-
phages, CO inhibited the production of pro-inflammatory cy-
tokines,  such  as  tumor  necrosis  factor-α (TNF-α),  inter-
leukin-1β (IL-1β), and macrophage inflammatory protein-1, 
through modulation of p38 MAPK activation (16). In human 
T cells, CO suppressed IL-2 secretion and clonal expansion 
via inhibition of ERK pathway (17). CO also suppressed the 
expression  of  pro-inflammatory  enzymes,  such  as  inducible 
nitric oxide synthase and cyclo-oxygenase-2, in macrophages 
by virtue of its ability to regulate the C/EBP and nuclear fac-
tor-κB (NF-κB) activation (18). In human colonic epithelial 
cells, the inhibitory effects of CO on iNOS expression and IL-6 
secretion were dependent on the modulation of NF-κB, acti-
vator protein-1 (AP-1), C/EBP activation, and MAPK pathway 
(19). 
BV/BR
The natural antioxidant BV/BR appears to substitute for some 
anti-inflammatory effects of HO-1 (20). The anti-inflammatory 
effects of BV on organ transplantation are manifested by de-
creased leukocyte infiltration, less T cell proliferation, and ex-
tended survival of allogeneic heart transplants (21). In the rat 
model of endotoxin-induced shock, BV reduced serum levels 
of  the  pro-inflammatory  cytokines,  but  enhanced  the  pro-
duction  of  the  anti-inflammatory  cytokines  (22).  BR  inhibited 
endothelial  cell  activation  by  suppressing  E-selectin  and  vas-
cular  cell  adhesion  molecule-1  expression  (23).  A  possible 
mechanism by which these effects of BV/BR occur may involve 
the inactivation of NF-κ B, a transcription factor strictly required 
for  the  transcription  of  the  pro-inflammatory  genes  (22,23). Heme Oxygenase-1: Its Therapeutic Roles in Inflammatory Diseases
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Ferritin expression
The expression of ferritin is markedly enhanced in conjunc-
tion with HO-1 expression (24). Although whether the ferritin 
could substitute for anti-inflammatory actions of HO-1 is not 
completely elucidated, it has been proven to be a potent anti-
oxidant enzyme (25). Ferrous iron, an extremely pro-oxida-
tive molecule that may cause inflammation, is released during 
the breakdown of free heme by HO-1 (24). In that case, the 
ferritin effectively sequesters the ferrous iron and, hence, lim-
its its pro-oxidant/pro-inflammatory capacity (24). Based on 
the  data  presented  by  Schaer  and  co-workers  (26),  the  in-
duction of HO-1 was directly involved in the down-regulation 
of inflammation, and this effect was due to ferritin synthesis 
as  a  result  of  HO-1  induction.
LESSONS FROM HO-1-DEFICIENT MICE
HO-1  plays important roles at least in the resolution of in-
flammation, and this concept is represented by the two genet-
ic findings: 1) the mice with HO-1 deficiency have a distinct 
phenotype of an increased inflammatory state (27,28) and 2) 
an inflammatory syndrome that developed in a HO-1-deficient 
human  patient  was  one  of  the  reasons  of  death  (29,30). 
Kapturczak and co-workers (27) examined the differences in 
immune  phenotype  between  HO-1  knockout  (HO-1
-/-)  and 
wild-type (HO-1
+/+) mice. The first finding is that a deficiency 
of  HO-1  may  predispose  to  generally  exaggerated  in-
flammatory responses, suggesting that its activity is necessary 
for timely resolution of early inflammation. The other is that 
HO-1
-/- splenocytes secreted disproportionately higher levels 
of  pro-inflammatory  cytokines  as  compared  to  those  from 
HO-1
+/+ mice, suggesting that HO-1 activity is also important 
in more downstream stages of the immune response. These 
two findings raise an important question as to how HO-1 can 
modulate  the  immune  response. 
  C D 4
+CD25
+  regulatory  T  (Treg)  cells  maintain  immuno-
logical  self-tolerance  and  limit  the  deleterious  effects  asso-
c i a t e d  w i t h  i n f l a m m a t o r y  r e a c t i o n s  ( 3 1 ) .  I n t e r e s t i n g l y ,  t h e r e  
are  the  similarities  in  the  anti-inflammatory  functions  attrib-
uted to Treg cells and to HO-1 activity, raising a possibility 
that HO-1 would be a key mediator of activities of Treg cells. 
Two studies have tested this hypothesis through the use of 
HO-1
-/- m i c e .  Z e l e n a y  a n d  c o - w o r k e r s  ( 3 1 )  h a v e  d e m o n -
strated  that  HO-1  is  not  essential  for  mouse  Treg  develop-
ment,  maintenance  and  function.  On  the  contrary,  George 
and co-workers (32) have demonstrated that a lack of HO-1 
in  antigen-presenting  cells  (APCs)  significantly  impairs  the 
suppressive function of  Treg cells  under conditions of  APC 
excess. The later would provide an explanation for the im-
munoregulatory  defects  observed  in  HO-1
-/- m i c e .  
ROLES OF HO-1 IN INFLAMMATORY DISEASES
In addition to valuable lessons from HO-1-deficient mice, the 
aforementioned properties of HO-1 and its by-products pro-
voked researchers’ interest in investigating the impact of HO-1 
on  the  development  of  inflammatory  diseases  in  animal 
models. Indeed, the cytoprotective effects of HO-1 have been 
well confirmed in a number of experimental models, includ-
ing  sepsis,  transplantation,  autoimmunity,  and  allergy. 
Sepsis
Sepsis  is  a  systemic  inflammation  against  severe  infection, 
which contributes to the cascade of events that ends not only 
in shock but also in multiple organ dysfunction and death. 
Despite  improved  therapy  and  better  understanding  of  the 
mechanisms underlying its pathogenesis, sepsis remains to be 
a  leading  cause  of  morbidity  and mortality in the intensive 
care  unit. 
    Symptoms of Gram-negative bacterial sepsis can be repro-
duced experimentally by administration of animals with lip-
opolysaccharide (LPS), a major component of the outer mem-
brane  of  Gram-negative  bacteria.  In  such  a  sepsis  model, 
macrophages are one of the cells that are most sensitive to 
LPS stimulation. Once activated in response to LPS, macro-
phages release endogenous mediators and defense molecules, 
including  pro-inflammatory  cytokines  such  as  TNF-α.  The 
pro-inflammatory  cytokines  could  protect  the  host  against 
bacterial infection, but an exaggerated stimulation of the im-
m u n e  s y s t e m  w i t h  a  m a r k e d  r e l e a s e  o f  c y t o k i n e s  c a n  l e a d  
to hypotension, collapse of circulatory system, multiple organ 
dysfunction, and death. The extent of cellular damage in the 
sepsis may be determined not only by the pro-inflammatory 
cytokines and enzymes but also by the anti-inflammatory cy-
tokines and enzymes. Among the anti-inflammatory enzymes, 
HO-1 has been shown to mediate protective effects in LPS-in-
duced sepsis model: there is accumulating evidence empha-
sizing the importance of HO-1 in the development of sepsis 
(33-41).  It  has  been  suggested  that  administration  of  mice 
with LPS was associated with a marked increase HO-1 gene 
expression in a site specific organ manner (42). Interestingly, 
HO-1 expression in monocytes from patients with severe sep-Heme Oxygenase-1: Its Therapeutic Roles in Inflammatory Diseases
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sis  significantly  increased,  as  compared  with  that  in  mono-
cytes  from  healthy  volunteers  (43).  The  possible  roles  of 
HO-1 in LPS-induced sepsis have been well characterized us-
ing  HO-1-deficient  mice.  HO-1-deficient  mice  develop  in-
creased end-organ damage and have increased mortality after 
LPS administration (41). In contrast, administration of CO to 
HO-1-deficient  animals  attenuates  LPS-induced  inflammation 
and end-organ injury (44). These studies support the benefi-
cial effects of HO-1 and its by-products such as CO during 
sepsis. 
Graft rejection
Organ transplantation has become an ultimate therapeutic op-
tion for irreversible organ failure. Early graft survival has sig-
nificantly improved; however, the long-term outcome remains 
unsatisfactory. Long-term graft function and graft survival are 
affected by both non-immunologic and immunologic factors. 
Ischemia reperfusion (IR) injury represents the major non-im-
munologic factor implicated in the pathogenesis of graft dys-
function and activation of alloreactive T cells, mainly due to 
failure of transplantation tolerance, is served as the major im-
munologic  factor. 
    There is accumulating evidence to support the notion that 
HO-1 expression in a graft and in the recipient can prevent 
graft rejection and promote immune tolerance (45-57). Under 
a given immunosuppressive regimen, the survival of a mouse 
heart  transplanted  into  a  rat  was  related  to  high  levels  of 
HO-1  expression  in  the  graft  vasculature  (58).  Hearts  from 
HO-1-deficient mice failed to survive when transplanted un-
der  the  same  immunosuppressive  regimen  (51),  suggesting 
that HO-1 expression in transplants from wild-type mice con-
tributes in a critical manner to sustain their survival. This no-
tion  has  now  been  expanded  by  showing  that  HO-1  ex-
pression can inhibit different processes involved in IR injury 
as well as in the acute and chronic rejection of transplanted 
organs  (59).  IR  injury  triggers  a  pro-inflammatory  response 
in the graft, which in turn augments graft immunogenicity and 
as  such  results  causes  graft  dysfunction.  Endogenous  HO-1 
expression  inhibited  IR  injury  during  organ  transplantation 
(60), and this is the first explanation regarding how HO-1 can 
promote  graft  survival.  The  protective  effects  of  HO-1  may 
be mediated via several pathways: removal of free heme gen-
erated during IR injury, antioxidant properties of BV/BR, and 
vasoregulatory effects as well as anti-inflammatory, anti-apop-
totic, and antiproliferative properties of CO. The second ex-
planation  is  that  HO-1  was  also  involved  in  transplantation 
tolerance (61). The tolerogenic effect of HO-1 was found de-
pendent  on  the  activation  of  CD4
+CD25
+  Treg  cells  (51).
Autoimmune disease
Autoimmunity  occurs  when  the  immune  system  recognizes 
and attacks host tissue. In addition to genetic factors, environ-
mental triggers are thought to play a major role in the devel-
opment  of  autoimmune  diseases.  Autoimmune  diseases  fall 
into  two  general  types:  those  that  damage  many  organs 
(systemic autoimmune diseases) and those where only a sin-
gle organ or tissue is directly damaged by the autoimmune 
process  (localized).  Examples  of  autoimmune  diseases  in-
clude type I diabetes, multiple sclerosis, rheumatoid arthritis 
(RA),  and  lupus. 
    HO-1  is  considered  as  an  endogenous  factor  responsible 
for the resolution of inflammation and might thus be a novel 
target  for  the  modulation  of  the  inflammatory  autoimmune 
response. Recently, several investigators have presented evi-
dence  to  support  an  immunosuppressive  function  of  HO-1 
during the course of autoimmune diseases (62-69). Hu and 
co-workers (64) evaluated the effect of HO-1 on autoimmune 
diabetes. Using NOD mice which spontaneously develop type 
I diabetes, they showed that intravenous HO-1 transduction 
reduced destructive insulitis and the incidence of overt dia-
betes by down-regulating the phenotypic maturity of dendritic 
c e l l s  a n d  T h 1  e f f e c t o r  f u n c t i o n .  A  s i m i l a r  p r o t e c t i v e  e f f e c t  
against  diabetes was  also  observed  in  NOD  mice subjected 
to CO (70). Chora and co-workers (66) reported that HO-1 
expression dictated the pathologic outcome of experimental 
autoimmune  encephalomyelitis  (EAE),  a  model  of  multiple 
sclerosis, and pharmacological induction of HO-1 suppressed 
the  pathologic  outcome  of  autoimmune  neuro-inflammation 
associated with the development of EAE, presumably by in-
hibiting the expression of MHC class II on APCs and the re-
activation of pathogenic CD4
+ T cells within the central nerve 
system.  Kobayashi  and  co-workers  (67)  examined  the  ex-
pression and pathogenetic roles of HO-1 in RA,  and found 
that HO-1 expressed in RA synovial tissues protected against 
the  onset  of  RA. 
Allergic disease
Allergic  reactions  differ  from  protective  immune  reactions 
(immunity) only in that they are exaggerated or inappropriate 
and damaging to the host (hypersensitivity). The cellular and 
molecular mechanisms of the two types of reaction are vir-
tually identical. The sequence of events involved in the devel-Heme Oxygenase-1: Its Therapeutic Roles in Inflammatory Diseases
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opment of allergic reaction can be divided into three phases: 
the sensitization phase, during which immunoglobulin E (IgE) 
is produced in response to allergenic stimulus and binds to 
specific receptors on mast cells and basophils; the activation 
phase, during which re-exposure to allergen triggers the mast 
cells and basophils to release of the contents of their gran-
ules;  and  the  effector  phase,  during  which  an  anaphylactic 
re sp on se  o cc u rs as a  re su lt  o f r el ea se  of  ph ar ma co lo g ic al ly 
active agents. After subsidence of acute reaction, localized in-
flammation  is elicited  by  the mediators released  during the 
course  of  immediate  reaction  as  late-phase  reaction. 
    HO-1 expression is up-regulated in allergic triad (asthma, 
allergic  rhinitis,  and  atopic  dermatitis),  and  HO-1  has  been 
proven to be anti-allergic (71). Almolki and co-workers (72) 
reported  the  anti-allergic  role  of  HO-1  in  allergic  airway 
inflammation. The guinea pigs were sensitized with ovalbu-
min (OVA) to develop characteristic features of asthma, and 
treated with the HO-1 inducer hemin during sensitization or 
after developing impaired airways features. Oxidative stress 
in  OVA-challenged  animals  and  the  number  of  neutrophils, 
eosinophils, and lymphocytes in their airways were markedly 
reduced when HO-1 expression was induced by hemin, sug-
gesting a protective role of HO-1 against airway inflammation. 
Kirino  and  co-worker  (73)  have  demonstrated  that  serum 
HO-1 levels are increased in patients with atopic dermatitis 
(AD) and that the levels correlate with the severity of clinical 
manifestations and conventional disease markers. In an AD 
mouse  model,  HO-1  was  abundantly  expressed  in  resident 
macrophages and DCs in the AD-like skin lesions. Interesting-
ly, pharmacologic induction of HO-1 suppressed the develop-
ment  of  these  AD-like  skin  lesions,  suggesting  a  protective 
role of HO-1 against skin inflammation. At present, the exact 
mechanisms by which HO-1 could exert anti-allergic effects 
have not been completely elucidated. In addition to the anti-
oxidant/anti-inflammatory properties of HO-1 and its by-prod-
ucts, blockage of mast cell activation (74), inhibition of IgE 
production (75), and modulation of immunological functions 
of T cells and DCs (76) might mediate anti-allergic effects of 
HO-1.
CONCLUSION
During the last decade, the beneficial roles that HO-1 could 
play in a number of disease states have been elucidated, and 
the  protective/anti-inflammatory  role  of  HO-1  has  been 
highlighted. In the present review, we have briefly summar-
ized the current data confirming the beneficial effects of HO-1 
on inflammatory diseases. It is now commonly accepted that 
HO-1 plays  a  crucial  role in the  resolution  of inflammation 
(71,77). For examples, mice lacking HO-1 were more suscep-
tible to inflammatory injury (27,28), whereas the use of phar-
macological agents and genetic probes for up-regulating HO-1 
expression rendered experimental animals less susceptible to 
inflammation  (33-43).  Although  the  exact  mechanism(s)  by 
which HO-1 can exert anti-inflammatory effects has not yet 
been elucidated, its metabolic products have been shown to 
mimic anti-inflammatory actions of HO-1. The use of CO and 
BV/BR as therapeutic agents has been successful in some in-
flammatory models. Based on the current researches focusing 
on the anti-inflammatory roles of HO-1 or its metabolic prod-
ucts, we suggest that the strategies to target HO-1 or its meta-
bolic  products  may  offer  promising  therapeutic  approaches 
for  the effective  management of  a  number  of inflammatory 
diseases. 
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72. Almolki A, Taillé C, Martin GF, Jose PJ, Zedda C, Conti M, 
Megret J, Henin D, Aubier M, Boczkowski J: Heme oxygen-
ase  attenuates  allergen-induced  airway  inflammation  and 
hyperreactivity in guinea pigs. Am J Physiol Lung Cell Mol 
Physiol  287;L26-L34,  2004
73. Kirino M, Kirino Y, Takeno M, Nagashima Y, Takahashi K, 
Kobayashi M, Murakami S, Hirasawa T, Ueda A, Aihara M, 
Ikezawa  Z,  Ishigatsubo  Y:  Heme  oxygenase  1  attenuates 
the development of atopic dermatitis-like lesions in mice: 
implications  for  human  disease.  J  Allergy  Clin  Immunol 
122;290-297,  2008
74. Takamiya R, Murakami M, Kajimura M, Goda N, Makino 
N,  Takamiya  Y,  Yamaguchi  T,  Ishimura  Y,  Hozumi  N, 
Suematsu M: Stabilization of mast cells by heme oxygen-
ase-1: an anti-inflammatory role. Am J Physiol Heart Circ 
Physiol  283;H861-H870,  2002
75. Vannacci A, Baronti R, Zagli G, Marzocca C, Pierpaoli S, 
Bani D, Passani MB, Mannaioni PF, Masini E: Carbon mon-
oxide  modulates  the  response  of  human  basophils  to 
FcepsilonRI stimulation through the heme oxygenase path-
w a y .  E u r J  P h a r m a c o l 4 6 5 ;2 8 9 - 2 9 7 , 2 0 0 3
76. Xia ZW, Xu LQ, Zhong WW, Wei JJ, Li NL, Shao J, Li YZ, 
Yu  SC,  Zhang  ZL:  Heme  oxygenase-1  attenuates  ovalbu-
min-induced  airway  inflammation  by  up-regulation  of 
foxp3  T-regulatory  cells,  interleukin-10,  and  membrane- 
bound  transforming  growth  factor-1.  Am  J  Pathol  171; 
1904-1914,  2007 
77. Rushworth  SA,  O'Connell  MA:  Haem  oxygenase-1  in 
inflammation.  Biochem  Soc  Trans  32;1093-1094,  2004